Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

The approval of olaratumab is very exciting to treat advanced soft tissue sarcoma as this is an important advance to patients. It is the first FDA approval in first-line treatment for these patients in 40 years, Melemed explains.

Additionally, sarcoma is a very heterogenous disease comprised of more than 50 subtypes. Other ongoing clinical trials are looking at combination regimens of olaratumab and chemotherapy.

Videos

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Symantha Melemed, PhD

Articles

The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma